Brookline Cap M Comments on CervoMed FY2025 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Cap M issued their FY2025 EPS estimates for CervoMed in a research note issued on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed anticipates that the company will post earnings per share of ($2.65) for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Cap M also issued estimates for CervoMed’s Q4 2025 earnings at ($0.78) EPS.

CRVO has been the subject of several other reports. Brookline Capital Acquisition raised CervoMed to a “strong-buy” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of CervoMed in a research report on Thursday, December 18th. Roth Mkm set a $20.00 price objective on shares of CervoMed and gave the stock a “buy” rating in a research note on Friday, October 17th. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Finally, D. Boral Capital restated a “buy” rating and issued a $31.00 target price on shares of CervoMed in a report on Tuesday, December 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.17.

CervoMed Price Performance

Shares of CervoMed stock traded up $0.71 during trading hours on Friday, reaching $5.31. The company’s stock had a trading volume of 105,761 shares, compared to its average volume of 81,486. The firm has a 50 day moving average price of $7.45 and a 200-day moving average price of $8.16. The stock has a market cap of $49.13 million, a P/E ratio of -1.83 and a beta of -0.82. CervoMed has a one year low of $1.92 and a one year high of $16.94.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Friday, November 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). CervoMed had a negative net margin of 415.27% and a negative return on equity of 76.78%. The business had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $1.43 million.

Insider Transactions at CervoMed

In other news, CEO John J. Alam acquired 10,807 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was purchased at an average cost of $8.46 per share, for a total transaction of $91,427.22. Following the completion of the acquisition, the chief executive officer directly owned 1,484,078 shares of the company’s stock, valued at $12,555,299.88. The trade was a 0.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sylvie Gregoire acquired 10,807 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was acquired at an average cost of $8.46 per share, with a total value of $91,427.22. Following the completion of the purchase, the director owned 12,500 shares of the company’s stock, valued at $105,750. This trade represents a 638.33% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 92,000 shares of company stock valued at $737,723. 35.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares during the last quarter. Marshall Wace LLP purchased a new position in CervoMed during the second quarter valued at $76,000. Thompson Davis & CO. Inc. purchased a new stake in CervoMed during the 2nd quarter worth approximately $88,000. GSA Capital Partners LLP acquired a new position in CervoMed in the 3rd quarter valued at $91,000. Finally, Byrne Asset Management LLC purchased a new position in shares of CervoMed in the fourth quarter worth about $116,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.